Ero Announces Result of Year-Long Value-Creation Initiative at Xavantina, Commences First Gold Concentrate Sales in Q4 2025 GlobeNewswire November 04, 2025 VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) — Ero Copper Corp. (TSX: ERO, NYSE: ERO) (“Ero” or the “Company”) is pleased to announce the results of a year-long effort to create additional value […]

NexGold Achieves Critical Permitting Milestone; Receives Final Federal Approval for the Goldboro Gold Project GlobeNewswire November 04, 2025 TORONTO, Nov. 04, 2025 (GLOBE NEWSWIRE) — NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company“) is pleased to announce that the Fisheries Act Authorizations (the “FAAs“) for the construction and operation of the Goldboro

Woof Gang Advances Fully Integrated Technology Solutions to Give Full Control to the Pet Parents and Drive Tech-Enabled Franchise Growth Woof Gang Launches New App That Offers a Seamless Booking and Management Experience for Both Pet Parents and Store Owners GlobeNewswire November 04, 2025 MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — Woof Gang Bakery &

Capital City Bank Appoints Alicia Williams-Ronan Chief Retail Officer GlobeNewswire November 04, 2025 TALLAHASSEE, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) — Capital City Bank today announced that Alicia Williams-Ronan has assumed the role of chief retail officer. She succeeds Randy Lashua, who will retire on December 31 after 20 years of service. In this role,

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates GlobeNewswire November 04, 2025 Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026 Updated Data from BEACON Phase 1/2 Trial

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 04, 2025 – Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update

REMINDER – Stella-Jones Will Hold a Conference Call to Discuss its Third Quarter Results GlobeNewswire November 04, 2025 MONTREAL, Nov. 04, 2025 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX:SJ). Open to: Investors, analysts and all interested parties Date: Wednesday November 5, 2025 Time: 10:00 AM Eastern Standard Time (EST) Live Webcast: https://meetings.lumiconnect.com/400-700-172-835 Call: (+1) 800 990

Blue Gold Strengthens Leadership Team with Appointment of Chief Technology Officer to Deliver Digital Strategy and Create Ecosystem for World's First Global Gold-Backed Digital Currency Proven innovator and technology executive Nathan Dionne to advance Blue Gold's mission of building the world's first gold-backed digital currency ecosystem GlobeNewswire November 04, 2025 NEW YORK, NY, Nov. 04,

Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM(R) to Prevent Cytomegalovirus in Kidney Transplantation Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of Standardly Prescribed Antiviral Treatment in High-Risk Kidney Transplant Recipients GlobeNewswire November 04, 2025 REHOVOT, Israel,

Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire November 04, 2025 Initial results of a Phase 1 / 2 open label study of AT-02, the company's lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented